Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.

Pericleous L, Amin M, Goeree R.

J Med Econ. 2019 May;22(5):478-487. doi: 10.1080/13696998.2019.1582535. Epub 2019 Mar 4.

PMID:
30757934
2.

Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada.

Patel V, Ahmed I, Podbielski D, Falvey H, Murray J, Goeree R.

J Med Econ. 2019 Apr;22(4):390-401. doi: 10.1080/13696998.2019.1572013. Epub 2019 Feb 4.

PMID:
30663456
3.

Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.

Goeree R, Chiva-Razavi S, Gunda P, Jain M, Jugl SM.

J Med Econ. 2019 Jan;22(1):45-52. doi: 10.1080/13696998.2018.1539400. Epub 2018 Nov 13.

PMID:
30346844
4.

DEVELOPMENT OF THE ONTARIO DECISION FRAMEWORK: A VALUES BASED FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT.

Krahn M, Miller F, Bayoumi A, Brooker AS, Wagner F, Winsor S, Giacomini M, Goeree R, Sch√ľnemann H, van der Velde G, Petersen S, Sikich N, Dhalla I.

Int J Technol Assess Health Care. 2018 Jan;34(3):290-299. doi: 10.1017/S0266462318000235.

PMID:
29987995
5.

Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network.

Ng C, Ye L, Noorduyn SG, Hux M, Thommes E, Goeree R, Ambrose A, Andrew MK, Hatchette T, Boivin G, Bowie W, ElSherif M, Green K, Johnstone J, Katz K, Leblanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney J, McGeer A, Poirier A, Powis J, Richardson D, Sharma R, Semret M, Smith S, Smyth D, Stiver G, Trottier S, Valiquette L, Webster D, McNeil SA; Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Investigators; Toronto Invasive Bacterial Diseases Network (TIBDN) Investigators.

Influenza Other Respir Viruses. 2018 Mar;12(2):232-240. doi: 10.1111/irv.12521. Epub 2018 Jan 24.

6.

Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.

Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD.

J Med Econ. 2018 Feb;21(2):163-173. doi: 10.1080/13696998.2017.1384737. Epub 2017 Oct 19.

PMID:
28945143
7.

Comparative Efficacy of Angiotensin II Antagonists in Essential Hypertension: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.

Tsoi B, Akioyamen LE, Bonner A, Frankfurter C, Levine M, Pullenayegum E, Goeree R, O'Reilly D.

Heart Lung Circ. 2018 Jun;27(6):666-682. doi: 10.1016/j.hlc.2017.06.721. Epub 2017 Jul 14. Review.

PMID:
28807582
8.

Relationship between hyperbaric oxygen therapy and quality of life in participants with chronic diabetic foot ulcers: data from a randomized controlled trial.

Li G, Hopkins RB, Levine MAH, Jin X, Bowen JM, Thabane L, Goeree R, Fedorko L, O'Reilly DJ.

Acta Diabetol. 2017 Sep;54(9):823-831. doi: 10.1007/s00592-017-1012-z. Epub 2017 Jun 12.

PMID:
28603808
9.

Correction: Summary of Glaucoma Diagnostic Testing Accuracy: An Evidence-Based Meta-Analysis.

Ahmed S, Khan Z, Si F, Mao A, Pan I, Yazdi F, Tsertsvadze A, Hutnik C, Moher D, Tingey D, Trope GE, Damji KF, Tarride JE, Goeree R, Akhtar O, Hodge W.

J Clin Med Res. 2017 Mar;9(3):231. doi: 10.14740/jocmr2643wc1. Epub 2017 Jan 25.

10.

Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report.

Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R.

Value Health. 2016 Sep - Oct;19(6):704-719. doi: 10.1016/j.jval.2016.06.001.

11.

Summary of Glaucoma Diagnostic Testing Accuracy: An Evidence-Based Meta-Analysis.

Ahmed S, Khan Z, Si F, Mao A, Pan I, Yazdi F, Tsertsvadze A, Hutnik C, Moher D, Tingey D, Trope GE, Damji KF, Tarride JE, Goeree R, Hodge W.

J Clin Med Res. 2016 Sep;8(9):641-9. doi: 10.14740/jocmr2643w. Epub 2016 Jul 30. Erratum in: J Clin Med Res. 2017 Mar;9(3):231.

12.
13.

Management of Hospital Formularies in Ontario: Challenges within a Local Health Integration Network.

Burke N, Bowen JM, Troyan S, Jegathisawaran J, Gosse C, Tonkin M, Kagoma S, Goeree R, Holbrook A.

Can J Hosp Pharm. 2016 May-Jun;69(3):187-93. Epub 2016 Jun 30.

14.

BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles.

Dunlop WC, Mullins CD, Pirk O, Goeree R, Postma MJ, Enstone A, Heron L.

Pharmacoeconomics. 2016 Oct;34(10):1051-65. doi: 10.1007/s40273-016-0427-7. Review.

15.

Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.

Goeree R, Villeneuve J, Goeree J, Penrod JR, Orsini L, Tahami Monfared AA.

J Med Econ. 2016 Jun;19(6):630-44. doi: 10.3111/13696998.2016.1151432. Epub 2016 Mar 1.

PMID:
26850122
16.

Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial.

Fedorko L, Bowen JM, Jones W, Oreopoulos G, Goeree R, Hopkins RB, O'Reilly DJ.

Diabetes Care. 2016 Mar;39(3):392-9. doi: 10.2337/dc15-2001. Epub 2016 Jan 6.

PMID:
26740639
17.

Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension.

Akioyamen L, Levine M, Sherifali D, O'Reilly D, Frankfurter C, Pullenayegum E, Goeree R, Tsoi B.

J Am Soc Hypertens. 2016 Jan;10(1):55-69.e1. doi: 10.1016/j.jash.2015.11.005. Epub 2015 Dec 1.

PMID:
26684588
18.

Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting.

Kamboj L, Oh P, Levine M, Kammila S, Casey W, Harterre D, Goeree R.

Int J Cardiol. 2016 Jan 15;203:893-9. doi: 10.1016/j.ijcard.2015.11.037. Epub 2015 Nov 10.

PMID:
26613572
19.
20.

Zrx Mcdm: A Fully Flexible Tool to Support The Local Adaptation of Multiple-Criteria Decision Criteria In Health Care.

Zah V, Thompson S, Berjan M, Goeree R.

Value Health. 2015 Nov;18(7):A703. doi: 10.1016/j.jval.2015.09.2634. Epub 2015 Oct 20. No abstract available.

21.

Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.

Moshyk A, Martel MJ, Tahami Monfared AA, Goeree R.

J Med Econ. 2016;19(2):181-92. doi: 10.3111/13696998.2015.1106546. Epub 2015 Nov 11.

PMID:
26453248
22.

Pulmonary Rehabilitation in Ontario: A Cross-Sectional Survey.

Bowen JM, Campbell K, Sutherland S, Bartlett A, Brooks D, Qureshi R, Goldstein R, Gershon AS, Prevost S, Samis L, Kaplan AG, Hopkins RB, MacDougald C, Nunes E, O'Reilly DJ, Goeree R.

Ont Health Technol Assess Ser. 2015 Mar 1;15(8):1-67. eCollection 2015.

23.

Colon Capsule Endoscopy for the Detection of Colorectal Polyps: An Economic Analysis.

Palimaka S, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2015 Jul 1;15(15):1-43. eCollection 2015.

24.

Capsule Endoscopy in the Assessment of Obscure Gastrointestinal Bleeding: An Economic Analysis.

Palimaka S, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2015 Feb 1;15(2):1-32. eCollection 2015. Review.

25.

Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments.

Boutis K, von Keyserlingk C, Willan A, Narayanan UG, Brison R, Grootendorst P, Plint AC, Parker M, Goeree R.

Ann Emerg Med. 2015 Nov;66(5):455-463.e4. doi: 10.1016/j.annemergmed.2015.05.027. Epub 2015 Jul 14.

PMID:
26187612
26.

Barriers and facilitators influencing ethical evaluation in health technology assessment.

Assasi N, Schwartz L, Tarride JE, O'Reilly D, Goeree R.

Int J Technol Assess Health Care. 2015 Jan;31(3):113-23. doi: 10.1017/S026646231500032X.

PMID:
26179275
27.

Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations.

Tsoi B, O'Reilly D, Jegathisawaran J, Tarride JE, Blackhouse G, Goeree R.

BMC Res Notes. 2015 Jun 17;8:244. doi: 10.1186/s13104-015-1202-0. Review.

28.

Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management.

Tsoi B, Blackhouse G, Ferrazzi S, Reade CJ, Chen I, Goeree R.

Clinicoecon Outcomes Res. 2015 Apr 17;7:213-25. doi: 10.2147/CEOR.S78115. eCollection 2015.

29.

Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies.

Tsoi B, Goeree R, Jegathisawaran J, Tarride JE, Blackhouse G, O'Reilly D.

Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):451-63. doi: 10.1586/14737167.2015.1021336. Epub 2015 Mar 2. Review.

PMID:
25728942
30.

Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.

Tsoi B, O'Reilly D, Masucci L, Drummond M, Goeree R.

J Popul Ther Clin Pharmacol. 2015;22(1):e78-89. Epub 2015 Feb 21.

PMID:
25715384
31.

Evidence-based decision-making 3: Health technology assessment.

O'Reilly D, Campbell K, Vanstone M, Bowen JM, Schwartz L, Assasi N, Goeree R.

Methods Mol Biol. 2015;1281:417-41. doi: 10.1007/978-1-4939-2428-8_25.

PMID:
25694325
32.

A literature review of economic evaluations for a neglected tropical disease: human African trypanosomiasis ("sleeping sickness").

Sutherland CS, Yukich J, Goeree R, Tediosi F.

PLoS Negl Trop Dis. 2015 Feb 5;9(2):e0003397. doi: 10.1371/journal.pntd.0003397. eCollection 2015 Feb. Review.

33.

Economic burden of illness associated with diabetic foot ulcers in Canada.

Hopkins RB, Burke N, Harlock J, Jegathisawaran J, Goeree R.

BMC Health Serv Res. 2015 Jan 22;15:13. doi: 10.1186/s12913-015-0687-5.

34.

Processes, contexts, and rationale for disinvestment: a protocol for a critical interpretive synthesis.

Wilson MG, Ellen ME, Lavis JN, Grimshaw JM, Moat KA, Shemer J, Sullivan T, Garner S, Goeree R, Grilli R, Peffer J, Samra K.

Syst Rev. 2014 Dec 11;3:143. doi: 10.1186/2046-4053-3-143.

35.

Economic evaluation of an influenza immunization strategy of healthy children.

Gregg M, Blackhouse G, Loeb M, Goeree R.

Int J Technol Assess Health Care. 2014 Oct;30(4):394-9. doi: 10.1017/S0266462314000397. Epub 2014 Nov 21.

PMID:
25412647
36.

Utility values for pre-menopausal women suffering from symptomatic uterine fibroids.

Hux M, Ng C, Ortega GL, Ferrazzi S, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):181-9. doi: 10.1586/14737167.2015.965153. Epub 2014 Oct 4.

PMID:
25284595
37.

Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.

Diaby V, Goeree R, Hoch J, Siebert U.

Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):13-9. doi: 10.1586/14737167.2015.965155. Epub 2014 Sep 30.

PMID:
25267699
38.
39.

Impact of emergency department probiotic treatment of pediatric gastroenteritis: study protocol for the PROGUT (Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment) randomized controlled trial.

Freedman SB, Williamson-Urquhart S, Schuh S, Sherman PM, Farion KJ, Gouin S, Willan AR, Goeree R, Johnson DW, Black K, Schnadower D, Gorelick MH; Pediatric Emergency Research Canada (PERC) Gastroenteritis Study Group.

Trials. 2014 May 14;15:170. doi: 10.1186/1745-6215-15-170.

40.

Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.

Xie F, Hopkins RB, Burke N, Habib M, Angelis CD, Pasetka M, Giotis A, Goeree R.

Hosp Pract (1995). 2014 Apr;42(2):38-45. doi: 10.3810/hp.2014.04.1102.

PMID:
24769783
41.

The reporting of observational clinical functional magnetic resonance imaging studies: a systematic review.

Guo Q, Parlar M, Truong W, Hall G, Thabane L, McKinnon M, Goeree R, Pullenayegum E.

PLoS One. 2014 Apr 22;9(4):e94412. doi: 10.1371/journal.pone.0094412. eCollection 2014. Review.

42.

Evaluation of a chronic disease management system for the treatment and management of diabetes in primary health care practices in Ontario: an observational study.

O'Reilly DJ, Bowen JM, Sebaldt RJ, Petrie A, Hopkins RB, Assasi N, MacDougald C, Nunes E, Goeree R.

Ont Health Technol Assess Ser. 2014 Apr 1;14(3):1-37. eCollection 2014.

43.

Systematic review on the patient-reported outcomes of tissue-expander/implant vs autologous abdominal tissue breast reconstruction in postmastectomy breast cancer patients.

Tsoi B, Ziolkowski NI, Thoma A, Campbell K, O'Reilly D, Goeree R.

J Am Coll Surg. 2014 May;218(5):1038-48. doi: 10.1016/j.jamcollsurg.2014.02.011. Epub 2014 Feb 19. Review. No abstract available.

PMID:
24745568
44.

Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review.

Assasi N, Schwartz L, Tarride JE, Campbell K, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):203-20. doi: 10.1586/14737167.2014.894464. Review.

PMID:
24625039
45.

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada.

Grima DT, Brown ST, Kamboj L, Bainey KR, Goeree R, Oh P, Ramanathan K, Goodman SG.

Clinicoecon Outcomes Res. 2014 Jan 24;6:49-62. doi: 10.2147/CEOR.S51052. eCollection 2014.

46.

Safety of tissue expander/implant versus autologous abdominal tissue breast reconstruction in postmastectomy breast cancer patients: a systematic review and meta-analysis.

Tsoi B, Ziolkowski NI, Thoma A, Campbell K, O'Reilly D, Goeree R.

Plast Reconstr Surg. 2014 Feb;133(2):234-49. doi: 10.1097/01.prs.0000436847.94408.11. Review.

PMID:
24469159
47.

Vitamin B12 intramuscular injections versus oral supplements: a budget impact analysis.

Masucci L, Goeree R.

Ont Health Technol Assess Ser. 2013 Nov 1;13(24):1-24. eCollection 2013. Review.

48.

Point-of-Care Hemoglobin A1c Testing: A Budget Impact Analysis.

Chadee A, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2014 Jul 1;14(9):1-23. eCollection 2014.

49.

Surrogate outcomes: experiences at the Common Drug Review.

Rocchi A, Khoudigian S, Hopkins R, Goeree R.

Cost Eff Resour Alloc. 2013 Dec 17;11(1):31. doi: 10.1186/1478-7547-11-31.

50.

How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.

Diaby V, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):81-99. doi: 10.1586/14737167.2014.859525. Epub 2013 Dec 13. Review.

PMID:
24328890

Supplemental Content

Loading ...
Support Center